시장보고서
상품코드
1714320

피부과 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 용도별, 약물 종류별, 지역별, 경쟁별(2020-2030년)

Dermatological Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Application, By Drug Class, By Region, & Competition, 2020-2030F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 182 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

피부과 치료제 시장은 2024년 218억 달러로 평가되며, 2030년에는 352억 5,000만 달러에 달할 것으로 예상되며, 연평균 8.30%의 성장률을 보일 것으로 예상됩니다.

이 시장에는 여드름이나 습진과 같은 흔한 질환부터 건선이나 피부암과 같은 심각한 질환에 이르기까지 피부, 모발, 손톱, 점막에 영향을 미치는 질환의 진단과 치료가 포함됩니다. 피부 질환의 유병률 증가, 피부 건강에 대한 인식 증가, 생물학적 제제 및 맞춤형 의료 기술의 발전으로 인해 피부과 치료에 대한 수요가 증가하고 있습니다. 전 세계적으로 고령화가 진행되고 미용에 대한 관심이 높아짐에 따라 의료 및 미용 피부 치료에 대한 관심이 높아지고 있습니다. 특히 신흥 시장의 가처분 소득의 증가는 피부과 의료에 대한 폭넓은 접근을 가능하게 하고 있습니다. 제약 혁신과 디지털 헬스 트렌드는 피부과 질환의 진단 및 관리 방법을 재구성하고 이 분야의 지속가능한 성장을 촉진할 태세를 갖추고 있습니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 218억 달러
시장 규모 : 2030년 352억 5,000만 달러
CAGR : 2025-2030년 8.30%
급성장 부문 항감염증약
최대 시장 북미

시장 촉진요인

피부질환 유병률 증가

주요 시장 과제

제네릭 의약품 경쟁

주요 시장 동향

맞춤형 의료

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 피부과 치료제 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 용도별(탈모, 헤르페스, 건선, 주사, 아토피 피부염, 기타)
    • 약물 종류별(항감염제, 코르티코스테로이드, 항여드름제, 칼시뉴린 억제제, 레티노이드, 기타)
    • 지역별
    • 기업별(2024년)
  • 시장 맵

제6장 북미의 피부과 치료제 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 피부과 치료제 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 유럽 : 국가별 분석
    • 독일
    • 영국
    • 이탈리아
    • 프랑스
    • 스페인

제8장 아시아태평양의 피부과 치료제 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제9장 남미의 피부과 치료제 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 피부과 치료제 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병

제13장 세계의 피부과 치료제 시장 : SWOT 분석

제14장 경쟁 구도

  • Abbvie Inc.(Allergan PLC)
  • Almirall SA
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Galderma SA
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company.

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm 25.05.13

The Dermatological Therapeutics Market was valued at USD 21.80 billion in 2024 and is projected to reach USD 35.25 billion by 2030, growing at a CAGR of 8.30%. This market encompasses the diagnosis and treatment of conditions affecting the skin, hair, nails, and mucous membranes, including common ailments like acne and eczema, as well as serious diseases such as psoriasis and skin cancer. Demand for dermatological treatments is rising due to the growing prevalence of skin disorders, increasing awareness around skin health, and technological advances in biologics and personalized medicine. As the global population ages and aesthetic concerns gain prominence, the market is experiencing heightened interest in both medical and cosmetic skin therapies. Expanding disposable incomes, particularly in emerging markets, are also enabling broader access to dermatological care. Pharmaceutical innovations and digital health trends are poised to reshape how dermatological conditions are diagnosed and managed, driving sustained growth in the sector.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 21.80 Billion
Market Size 2030USD 35.25 Billion
CAGR 2025-20308.30%
Fastest Growing SegmentAnti-infectives
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Skin Disorders

The increasing global burden of skin diseases is a primary driver of the Dermatological Therapeutics Market. Skin disorders affect approximately 1.8 billion people worldwide, with estimates suggesting that 30% to 70% of the population experiences some form of dermatological condition at any given time. This widespread prevalence underscores a strong, sustained demand for effective skin treatments. Common conditions such as acne, eczema, psoriasis, atopic dermatitis, rosacea, and various infections are becoming more frequent across all age groups. This expanding patient pool presents a significant opportunity for pharmaceutical companies to develop and market innovative dermatological solutions. Additionally, growing awareness of skin health, driven by social media and increasing focus on aesthetics, further boosts demand for both therapeutic and cosmetic dermatology products. The persistent rise in skin disease incidence makes dermatology one of the most essential and dynamic sectors in healthcare, reinforcing its critical role in global medical infrastructure.

Key Market Challenges

Generic Competition

Generic competition poses a significant challenge to branded pharmaceutical companies operating in the dermatological therapeutics space. Once the patent protection for a drug expires, generic alternatives enter the market, often at significantly lower prices. This price disparity leads to erosion of market share and revenue for original branded products. The transition to generics intensifies pricing pressures, driving down profit margins and fragmenting the market with numerous similar products. Healthcare providers and insurers increasingly favor generics to reduce treatment costs, further impacting demand for branded therapies. For patients and dermatologists, a growing array of generic options can create confusion and complicate prescribing decisions. As the volume of generics increases, innovation may slow due to reduced financial incentives for R&D in new dermatological treatments, challenging companies to maintain competitiveness in a cost-sensitive environment.

Key Market Trends

Personalized Medicine

Personalized medicine is reshaping the landscape of dermatological therapeutics by offering targeted, individualized treatment approaches based on a patient's genetic profile, biomarkers, and disease characteristics. Advances in genomics enable the identification of genetic markers linked to specific skin conditions, such as psoriasis or melanoma, leading to tailored therapeutic interventions. Biomarker analysis allows dermatologists to predict patient responses to certain drugs and monitor disease progression more accurately. The use of biologics and small molecule inhibitors designed to target specific disease pathways has significantly improved outcomes for patients with severe dermatological conditions. Additionally, customized topical formulations-developed in collaboration with compounding pharmacies-address individual needs related to skin type and sensitivities. Personalized medicine also enhances risk stratification and prevention strategies for skin cancers and chronic inflammatory skin diseases. This trend is driving better clinical results, minimizing side effects, and marking a shift toward more effective and proactive dermatological care.

Key Market Players

  • Abbvie Inc. (Allergan PLC)
  • Almirall SA
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Galderma SA
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

Report Scope:

In this report, the Global Dermatological Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatological Therapeutics Market, By Application:

  • Alopecia
  • Herpes
  • Psoriasis
  • Rosacea
  • Atopic Dermatitis
  • Other

Dermatological Therapeutics Market, By Drug Class:

  • Anti-infectives
  • Corticosteroids
  • Anti-acne
  • Calcineurin Inhibitors
  • Retinoids
  • Other

Dermatological Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Therapeutics Market.

Available Customizations:

Global Dermatological Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Dermatological Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, Other)
    • 5.2.2. By Drug Class (Anti-infectives, Corticosteroids, Anti-acne, Calcineurin Inhibitors, Retinoids, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Dermatological Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Drug Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dermatological Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Drug Class
    • 6.3.2. Canada Dermatological Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Drug Class
    • 6.3.3. Mexico Dermatological Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Drug Class

7. Europe Dermatological Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Drug Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dermatological Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Drug Class
    • 7.3.2. United Kingdom Dermatological Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Drug Class
    • 7.3.3. Italy Dermatological Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Drug Class
    • 7.3.4. France Dermatological Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Drug Class
    • 7.3.5. Spain Dermatological Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Drug Class

8. Asia-Pacific Dermatological Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Drug Class
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Dermatological Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Drug Class
    • 8.3.2. India Dermatological Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Drug Class
    • 8.3.3. Japan Dermatological Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Drug Class
    • 8.3.4. South Korea Dermatological Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Drug Class
    • 8.3.5. Australia Dermatological Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Drug Class

9. South America Dermatological Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Drug Class
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Dermatological Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Drug Class
    • 9.3.2. Argentina Dermatological Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Drug Class
    • 9.3.3. Colombia Dermatological Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Drug Class

10. Middle East and Africa Dermatological Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Drug Class
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Dermatological Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Drug Class
    • 10.3.2. Saudi Arabia Dermatological Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Drug Class
    • 10.3.3. UAE Dermatological Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Dermatological Therapeutics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Abbvie Inc. (Allergan PLC)
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Almirall SA
  • 14.3. Amgen Inc.
  • 14.4. Bausch Health Companies Inc.
  • 14.5. Galderma SA
  • 14.6. GlaxoSmithKline PLC
  • 14.7. Johnson & Johnson
  • 14.8. Novartis AG
  • 14.9. Pfizer Inc.
  • 14.10.Bristol-Myers Squibb Company.

15. Strategic Recommendations

16. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제